Differences in effects of oncogenes on sensitivity to anticancer drugs

Journal of Radiation Research

Volumn 46, Issue 2, 2005, Pages 197-203

  Hamamoto, Tomoyuki ^a   Suzuki, Keiji ^b   Sasaki, Hitoshi ^a   Ichikawa, Masataka ^a   Kodama, Seiji ^b   Watanabe, Masami ^c  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Chemosensitivity; IC50; Oncogene; SHOK cells

Indexed keywords

CHEMOTHERAPY; ONCOGENIC VIRUSES;

ADRIAMYCIN; ANTICANCER DRUG; BLEOMYCINS; CHEMOSENSITIVITY; CIS-PLATIN; CISPLATIN; K-RAS GENE; MITOMYCIN C; SYRIAN HAMSTER OSAKA-KANAZAWA CELL; TRANSFECTANTS;

GENES;

MESOCRICETUS AURATUS;

ANTINEOPLASTIC AGENT; ONCOPROTEIN;

ANIMAL; ARTICLE; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HAMSTER; LD 50; METABOLISM; SYRIAN HAMSTER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; LETHAL DOSE 50; MESOCRICETUS; ONCOGENE PROTEINS;

EID: 23244454494     PISSN: 04493060     EISSN: None     Source Type: Journal    
DOI: 10.1269/jrr.46.197     Document Type: Article

References (37)

1. Tanaka, M. (2002) Chemoradiotherapy for lung, esophageal, and uterine cervix cancer. Nippon Acta Radiologica 62: 479-483.
2. Malas, L. and Cox, J. D. (2003) Principles of combining radiation therapy and chemotherapy. In: Radiation Oncology: Rationale, Technique, Results. 8th ed., Eds J. D. Cox and K. Kian Ang, pp. 108-121, Mosby, St. Louis.
3. Stewart, F. A. and Bartelink, H. (2002) The combination of radiotherapy and chemotherapy. In: Basic Clinical Radiobiology. 3rd ed., Ed G. G. Steel, pp.217-230, Arnold, London.
4. Calabresi, P. and Chabner, B. A. (2001) Chemotherapy of Neoplastic diseases, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed., Eds J. G. Hardman and L. E. Limbird, pp. 1381-1388, McGraw-Hill, New York.
5. Bos, J. L. (1989) ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
6. Field, J. K. and Spandidos, D. A. (1990) The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis(review). Anticancer Res. 10: 1-22.
7. Spandidos, D. A., Liloglou, T. and Field, J. K. (1993) Prognostic significance of oncogenes and tumor suppressor genes in human malignancy. Stem Cells 11: 194-198.
8. Duffy, M. J. (1995) Can molecular markers now be used for early diagnosis of malignancy?. Clin. Chem. 41: 1410-1413.
9. Sklar, M. D. (1988) Increased resistance to cis-diamminedichloroplatimum (II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res. 48: 793-797.
10. Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A. and Howell, S.B. (1991) Expression of c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res. 51: 5903-5909.
11. Peters, G. J., Wets, M., Keepers, Y. P. A. M., Oskam, R., Van Ark-Otte, J., Noordhuis, P., Smid, K. and Pinedo, H.M. (1993) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer 54: 450-455.
12. Toffoli, G., Viel, A., Tumiotto, L., Buttazzi, P., Biscontin G. and Boiocchi, M. (1989) Sensitivity pattern of normal and Haras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori, 75: 423-428.
13. Niimi, S., Nakagawa, K., Yokota, J., Tsunokawa, Y., Nishio, K., Terashima, Y., Shibuya, M., Terada, M. and Saijo, N. (1991) Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer 63: 237-241.
14. Wishart, G. C., Plumb, J. A., Spandidos, D. A. and Kerr, D. J. (1991) H-ras transfection in mink lung epithelial cells may induce "atypical" multidrug resistance. Eur. J. Cancer 27: 673.
15. Sklar, M.D. and Prochownik, E.V. (1991) Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 51: 2118-2123.
16. Le-Ruppert, K., Masters, J. R. W., Knuechel, R., Seegers, S., Tainsky, M. A., Hofstaedter F. and Buettner, R. (1992) The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activated N-ras oncogene. Int. J. Cancer 51: 646-651.
17. Van Waardenburg, R. C. A. M., Prins, J., Meijer, C., Uges, D. R. A., de Vries, E. G. E. and Mulder, N. H. (1996) Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res. 16: 1963-1970.
18. Gao, X., Asaumi, J., Kawasaki, S., Nishikawa, K., Kuroda, M., Takeda, Y., Hiraki, Y., Ihara M. and Ohnishi, T. (1995) Sensitivity of anticancer drugs in NIH3T3 cells transfected with oncogenes accompanied by pSV2neo vector. Anticancer Res. 15: 1911-1914.
19. Higashi, T., Sasai, H., Suzuki, F., Miyoshi, J., Ohuchi, T., Takai, S., Mori, T. and Kakunaga, T. (1990) Hamster cell line suitable for Transfection assay of transforming genes. Proc. Natl. Acad. Sci. USA 87: 2409-2413.
20. Suzuki, K., Watanabe M. and Miyoshi, J. (1992) Differences in effects of oncogenes on resistance to γ rays, ultraviolet light, and heat shock. Radiat. Res. 129: 157-162.
21. Ishiyama, M., Shiga, M., Sasamoto, K., Mizoguchi, M. and He, P. (1993) A new sulfonated tetrazolium salt that produces a highly water- soluble formazan dye. Chem. Pharm. Bull. 41: 1118-1122.
22. Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., Ueno, K. and Watanabe, M. (1995) Nobel cell proliferation and cytotoxicity assays using a tetrazolium salt that produces a water-soluble formazan dye. In vitro toxicol. 8: 187-190.
23. Poddevin, B., Orlowski, S., Belehradek, J. Jr. and Mir, L. M. (1991) Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem. Pharmacol. 42 (Suppl.): S67-S75.
24. R. T. Dorr (1992) Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin. Oncol. 19: 3-8.
25. Sikic, B. I. (1986) Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 5: 81-91.
26. Chabner, B. A., Ryan, D. P., Paz-Ares, L., Garcia-Carbonero, R. and Calbresi, P. (2001) Antineoplastic agents, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed., Eds J. G. Hardman and L. E. Limbird, pp. 1389-1459, McGraw-Hill, New York.
27. Andrews P. A. and Howell S. B. (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43.
28. Gao, X. (1995) Studies on sensitivity to adriamycin in NIH3T3 cells transfected with several oncogenes. Jpn. J. Hyperthermic Oncol. 11: 162-170.
29. Hisawa, T., Tokita, H. and Ike, Y. (1996) Differential chemosensitivitiy in oncogene-transformed cells. J. Exp. Ther. Oncol. 1: 162-170.
30. Sartorelli, A. C., Hodnick, W. F., Belcourt, M. F., Tomasz, M., Haffty, B., Fischer J. J. and Rockwell, S. (1994) Mitomycin C: a prototype bioreductive agent. Oncol. Res. 6: 501-508.
31. Gorgoulis, V. G., Zacharatos, P., Mariatos, G., Liloglou, T., Kokotas, S., Kastrinakis, N., Kotsinas, A., Athanasiou, A., Foukas, P., Zoumpourlis, V., Kletsas, D., Ikonomopoulos, J., Asimacopoulos, P. J., Kittas, C. and Field, J. K. (2001) Deregulated expression of c-mos in non-small cell lung carcinoma: relationship with p53 status, genomic instability, and tumor kinetics. Cancer Res. 61: 538-549.
32. Perunovic, B., Athanasiou, A., Quilty, R. D., Gorgoulis, V. G., Kittas, C. and Love, S. (2002) Expression of mos in astrocytic tumors and its potential role in neoplastic progression. Hum. Pathol. 33: 703-707.
33. Athanasiou, A., Perunovic, B., Quilty, R. D., Gorgoulis, V. G., Kittas, C. and Love, S. (2003) Expression of mos in ependymal gliomas. Am. J. Clin. Pathol. 120: 699-705.
34. Eliopoulos, A. G., Davies, C., Blake, S. S., Murray, P., Najafipour, S., Tsichlis, P. N. and Young, L. S. (2002) The oncogenic protein kinase Tpl-s/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-κB signaling downstream of TRAF2. J. Virol. 76: 4567-4579.
35. Ohara, R., Hirota, S., Onoue, H., Nomura, S., Kitamura, Y. and Toyoshima, K. (1995) Identification of the cells expressing cot proto-oncogene mRNA. J. Cell Sci. 108: 97-103.
36. Sourvinos, G., Tsatsanis, C. and Spandidos, D. A. (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18: 4968-4973.
37. Dhingra, K. and Hortobagyi, G. N. (1996) Critical evaluation of prognostic factors. Semin. Oncol. 23: 436-445.